Thursday, January 1, 2026

Mark Your Calendar

Zacks | Our Research. Your Success.

January 5 at 11 a.m. ET: Zacks Top 10 Stocks for 2026 Are Revealed

Zacks Member,

Hello, I'm Sheraz Mian, Director of Research for Zacks, and I want you to know that the New Year holds great promise for select stocks.

We're only a few days away from the release of Zacks Top 10 Stocks for 2026.

Investors who get in early on our best long-term buys for the year will position their portfolios for outperformance no matter what the market has in store.

Since inception in 2012, the Top 10 portfolios have more than QUADRUPLED the market.

While the S&P 500 gained +570.3%, Zacks Top 10 Stocks skyrocketed +2,530.8%

Each year, from the Zacks universe of more than 4,000 stocks, I handpick the 10 best to buy and hold for the entire year—strong, successful businesses, not just companies with potential.

A few of the new selections include:

Mission-Critical Safety Provider. This company provides safety and specialty services that customers can't cut, even in a slowdown. Their must-have model is driving strong recurring revenue and disciplined execution sets the stage for sustained earnings growth.
Standout Beneficiary of AI. This little-known chipmaker is perfectly positioned for the next wave of tech-driven demand at the heart of AI data centers, EVs and more. Its premium power solutions continue to drive revenue expansion and industry-leading margins.
Cash-Generating Powerhouse. With relentless demand for medical services, this company is a quiet giant moving trillions through the healthcare system. Its scale, pricing power and relentless demand make it a cash machine built for long-term gains and big dividend payouts.

Overall the portfolio is diversified with 7 more stocks from a variety of industries.

And remember, their potential value is greatest at the time of their release.

You can be among the first wave of investors to see this coveted list of 10 handpicked stocks the morning of Monday, January 5.

Happy Investing,

Sheraz Mian - signature
Sheraz Mian
Director of Research

No comments:

Post a Comment